A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator- Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (INTerpath-012).
Phase: Phase I-II clinical trials
Principal Investigator: Dott. Del Vecchio Michele
Main Facility: Oncologia Medica 1 - Unità Oncologia Medica Melanomi
Drug: Pembrolizumab, V940
Pathologies: Melanoma
ClinicalTrials.gov: Read more about clinical trials
This is a Phase 2, randomized, placebo- and active-controlled, parallel-group, multicenter, double-blind, safety and efficacy study of V940 plus pembrolizumab (Arm A) versus placebo plus pembrolizumab (Arm B) in first-line advanced melanoma. Participants must be untreated for advanced disease.
All participants must provide a blood sample and an FFPE tumor sample (obtained within 6 months before randomization, preferably from a metastatic site and, if not available, from the primary tumor) as soon as possible after consent for V940 generation. V940 generation should be prioritized. Randomization will only occur after the blood and FFPE tumor samples have passed the required QC checks by the Sponsor’s vendor, and the participant satisfies eligibility requirements.
Eligible participants will be randomly assigned in a 1:1 ratio to receive treatment with either V940 plus pembrolizumab or placebo plus pembrolizumab. Randomization will be stratified according to whether the participant received prior anti-PD-1 therapy and BRAF V600 status (mutation positive versus wild-type/unknown). BRAF V600 mutation status will be based on documentation, or the participant may have a tumor tissue sample tested locally during Screening.
Participants will receive treatment for up to 9 doses of either V940 or placebo q3w (once available), plus 17 cycles of pembrolizumab q6w, or until any of the criteria for discontinuation of study intervention are met.
Last update: 20/04/2026